Doloteffin – clinically proven efficacy

Doloteffin with degenerative diseases

  • Investigator: Dr. Wegener, Rheda-Wiedenbrück, Germany
  • Medication: Doloteffin, 2 coated tablets t.i.d.
  • Indication: Arthrosis of the hip and/or knee
  • Patients: 75
    38 patients with osteoarthritis of the knee
    21 patients with osteoarthritis of the hip
    16 patients with osteoarthritis of the knee and hip
  • Treatment duration: 12 weeks

Target parameters

  • Western-Ontario-McMaster-Universities-osteoarthritis index (WOMAC)
    Score from the components joint pain, stiffness and body function (10-point numerical score)
  • Clinical findings
    Pressure pain, physical impairment, joint noises, joint swelling, joint reddening, genral clinical state (4-point score)
  • Clinical global impression (CGI)
    Change of clinical state, therapeutic efficacy, tolerance
  • Tolerance / safety
    Adverse events, side effects

Change of WOMAC (10-point score, mean)

Improvement of clinical findings in relation to baseline (4-point score, mean)

  • Results: After 12 weeks there was an improvement of all assessment parameters:
    – Total-pain index by 25% (median: 28%)
    – WOMAC-total index by 26% (median: 29%)
    – WOMAC-index component stiffness 25% (median: 22%)
  • Improvement of clinical symptoms in the course of the therapy

Wegener and Lüpke, Phytotherapy Research 2003; 17:1165-1172.